A Phase 2a, Multicenter, Placebo-controlled, Randomized, Double-blind, Parallel-group Study to Evaluate the Efficacy and Safety of ONO-2020 in Patients With Agitation Associated With Alzheimer's Disease Dementia
Latest Information Update: 10 Jun 2025
At a glance
- Drugs ONO 2020 (Primary)
- Indications Alzheimer's disease; Dementia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Ono Pharmaceutical
Most Recent Events
- 24 Mar 2025 Status changed from not yet recruiting to recruiting.
- 05 Feb 2025 New trial record